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Aim
Resolution of acute anti-thy1 glomerulonephritis by itself
indicates an endogenous program of disease regression is
operating. Given the renoprotective effects of the
endothelial nitric oxide (NO)-cGMP pathway, the present
study analyzed expression and activity of NO-cGMP sign-
aling during a time course of acute anti-thy1 glomeru-
lonephritis.
Methods
Rats with anti-thy1 glomerulonephritis were sacrificed at
0.5 and 1 day (injury), 5 and 10 days (matrix expansion)
and 15 and 20 days (resolution) after OX-7 antibody
injection. Measures of disease activity included glomeru-
lar matrix accumulation, transforming growth factor-
beta1 (TGF-beta1) expression as well as glomerular plate-
let deposition, macrophage infiltration and cell prolifera-
tion. NO-cGMP signaling was characterized by measuring
glomerular NO and cGMP production as well as glomeru-
lar mRNA expression of endothelial NO synthase (eNOS),
inducible NOS (iNOS), alpha1 and beta1 soluble guan-
ylate cyclase (sGC) and phosphodiesterase-5 (PDE-5).
Results are expressed in relation to normal day 0 controls
(=100%) (*p < 0.05 versus normal day 0 controls).
Results
In the injury phase, mesangial cell lysis was paralleled by
markedly induced glomerular NO production (+673%*,
iNOS expression +742%*), but loss of NO-stimulated
glomerular cGMP production (-63%*) due to reduced
alpha1 (-63%*) and beta1 sGC expression(-63%*). Dis-
ruption of NO-cGMP signaling was followed by marked
increases in glomerular TGF-beta1 expression (+545%*),
matrix accumulation (+187%*), platelet deposition
(+5677%*), leukocyte infiltration (+513%*) and cell pro-
liferation (+432%*) at day 5 (matrix expansion phase).
Glomerular disease indicators returned towards normal at
day 20. Resolution of glomerular matrix expansion was
preceded by a significant up-regulation of NO-stimulated
glomerular cGMP (+8860%*), alpha1 (+1459%*) and
beta1 sGC (+972%*) and PDE-5 expression (+170%*) at
day 5.
Conclusion
An activation of the NO-cGMP pathway precedes resolu-
tion of acute anti-thy1 glomerulonephritis. Enhancing
NO-cGMP signaling, for instance by using activators of
soluble guanylate cyclase or inhibitors of PDE-5, may
serve as pharmacological approach for regressing tissue
fibrosis in established kidney disease.
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